Contact the ACC Registration and Housing Center

  • 864-208-2670
  • M-F, 9:00 a.m. - 5:00 p.m. ET
  • Questions? Learn more with our FAQs.

    Industry-Expert Theater

    Connect with the experts in the Industry-Expert Theaters as presenters share that latest in cardiovascular practices, services and technologies during these 60-minute focused sessions.

    Quick Links: SaturdaySundayMonday


    10:15 a.m. – 11:15 a.m.

    4001. Help Your Recent MI Patients Achieve Lower LDL-C and Reduce the Risk of Another MI
    Industry-Expert Theater 1
    Sponsored by Amgen

    Join Dr. Seth Baum for an educational presentation on the treatment of very high-risk ASCVD patients described in the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. Hear about his experience and the treatment options available for appropriate patients.

    Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

    4009. Advances and New Studies For the Treatment of MR With Abbott's TMV Repair and Replacement Therapies
    Industry-Expert Theater 2
    Sponsored by Abbott

    MR is prevalent and growing with only few patients being treated each year. Join us to learn about new TEER guidelines & treatment options for ALL your Mitral patients followed with a panel discussion.

    • Session 1: Achieve Highest MR Reduction With MitraClip™ and Learn About the New Recommendation on TEER in the ACC/AHA Valvular Guideline
    • Session 2: REPAIR MR Trial: Evaluating New Treatment Options For Moderate Risk Patients - Late Results For Functional MR to New Horizons For Primary MR
    • Session 3: The SUMMIT Tendyne Trial – A New Mitral Valve Replacement Option For Elimination of Severe MR

    Paul Grayburn, MD, FACC
    Medical Director, Baylor Scott and White Research imaging core lab
    Baylor Scott & White Heart & Vascular Hospital at Plano

    Michael J. Rinaldi, MD,
    Director, Structural Heart Programs, Sanger Heart & Vascular institute
    Atrium Health

    Patrick McCarthy, MD
    Executive Director, Bluhm Cardiovascular Institute
    Northwestern Medicine

    Jason Rogers, MD
    Director, Interventional Cardiology
    UC Davis Medical Center

    4017. Session Title to be Announced
    Industry-Expert Theater 3
    Sponsored by CSL Behring

    4025. Session Title to be Announced
    Industry-Expert Theater 4
    Sponsored by Edwards Lifesciences

    4033. Protected PCI: Diagnosis and Treatment of High-Risk and Complex Coronary Disease for Superior Long-term Outcomes
    Industry-Expert Theater 5
    Sponsored by Abiomed

    Many patients are often not diagnosed or not sent for treatment. This webinar will review contemporary data for the identification and treatment options for patients with complex and high risk coronary disease.

    • Data supporting Protected PCI Procedures? Restore EF, Protect III, Protect IV
    • Complete revascularization in Protected PCI patients in a single setting is safe and effective
    • Identifying the Ischemic Substrate in HFrEF
    • Panel Discussion

    William O'Neill, MD, FACC, FSCAI, FAHA
    Henry Ford Hospital, Detroit

    Jason Wollmuth, MD
    Providence Heart and Vascular Institute, Portland

    Gregg Stone, MD
    Columbia University, New York City

    Cindy Grines, MD
    Northside Cardiovascular Institute, Atlanta

    Susie Joseph, MD
    University of Maryland Medical Center, Baltimore

    12:45 p.m. – 1:45 p.m.

    4002. Session Title to be Announced
    Industry Expert Theater 1
    Sponsored by Amarin Pharma, Inc.

    4018. Beyond a Broken Heart: Multisystem Disease Burden in hATTR Amyloidosis
    Industry Expert Theater 3
    Sponsored by Alnylam Pharmaceuticals

    Join our distinguished faculty for a virtual Industry-Expert Theater (IET) presentation chaired by Dr. Noel Dasgupta to learn about the critical role of the cardiologist in diagnosing and monitoring for multisystem manifestations in patients with hereditary ATTR (hATTR) amyloidosis. Dr. Dasgupta will be joined by Dr. Farooq Sheikh and Dr. Jeffrey Shije and together they will provide insights on hATTR amyloidosis diagnosis, and how cardiologists can monitor patients for neurological impairment.

    Program will include educational presentations, a patient case discussion panel to review multisystem disease progression in patients with hATTR amyloidosis, and an audience Q&A.

    Noel Dasgupta, MD, FACC
    Associate Professor of Clinical Medicine and Pathology & Laboratory Medicine
    Krannert Institute of Cardiology, Indiana University

    Jeffrey Shije, MD
    Assistant Professor of Neurology, Neuromuscular Medicine
    University of Florida, Jacksonville FL

    Farooq H. Sheikh, MD, FACC
    Director, Infiltrative Cardiomyopathy Program; Assistant Professor of Medicine
    MedStar Heart and Vascular Institute; Georgetown University School of Medicine

    4026. Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Raising Awareness to Appropriately Identify, Diagnose and Treat Patients
    Industry Expert Theater 4
    Sponsored by Pfizer

    Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a rare, life-threatening, underrecognized, and underdiagnosed disease that frequently presents as heart failure. This presentation will provide an overview of ATTR-CM and highlight how to recognize the signs and symptoms that raise suspicion of ATTR-CM, while introducing approaches to achieve a differential diagnosis. The patient journey will be illustrated to understand the process of assessment to diagnosis. The program will end with a review of the clinical data for a treatment option for ATTR-CM.

    3:45 p.m. – 4:45 p.m.

    4003. Session Title To Be Announced
    Industry-Expert Theater 1
    Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC

    4019. Strategies for Bleeding Avoidance After Complex PCI
    Industry-Expert Theater 3
    Sponsored by Medtronic

    Join us for a live conversation around the challenges of balancing bleeding and ischemia in this challenging high bleeding risk patient population. When does it make sense to discontinue DAPT? What are your colleagues doing in real-world practice? We will review a few complex cases, discuss the best approach to DAPT post-PCI and the implications of recent data including the Onyx ONE Month DAPT Program.

    Mohamed Azeem Latibe, MD, MB BCh (Chair)
    Medical Director, Interventional Cardiology & Structural Heart Interventions
    Montefiore Medical Center

    James W. Choi,MD, FACC, FSCAI
    Director, Interventional Fellowships and Associate Professor, Texas A&M
    Baylor Heart and Vascular

    Wissam Jaber, MD
    Director, Cardiac Catheterization Laboratory and Associate Professor
    Emory University Hospital

    Tony Walton, MD, MBBS, FRACP, FCSANZ
    Director of the Carida Interventional Laboratories at Western Health and Associate
    Professor, Monash University
    The Alfred

    4027. Session Title To Be Announced
    Industry-Expert Theater 4
    Sponsored by Impulse Dynamics

    Sunday, May 16

    9:45 a.m. – 10:45 a.m.

    4004. Understanding the Impact of Lp(a) in ASCVD: A Focus on Added CV Risk, Guidelines, and Testing
    Industry-Expert Theater 1
    Sponsored by Amgen

    Come listen to a presentation with Dr. Prediman K. Shah about understanding the impact of Lp(a) in ASCVD with a focus on added CV risk, guidelines, and testing

    Prediman K. Shah, MD, MACC

    4020. Implementing Rhythm Control Guidelines in Atrial Fibrillation: The Good, The Bad, and The Ugly
    Industry-Expert Theater 3
    Sponsored by Sanofi

    Early rhythm management of atrial fibrillation is quickly emerging as an important consideration in getting the right treatment to the right patient at the right time.

    Recent updates of international guidelines and peer-reviewed publications should be shaping practice patterns, but there are challenges to implementation.

    This session will: 1/ discuss these challenges and share insights on how to increase guideline adherence; 2/ compare how patients are managed in the real world gleaned from the results of a new study: AIM-AF; 3/ identify gaps in the current guidelines and discuss areas that need further assessment via eminently upcoming trials addressing these gaps.

    Carina Blomström Lundqvist, MD
    Professor of Cardiology
    Institute of Medical Science (Sweden)

    Jonathan Paul Piccini, MD
    Associate Professor of Medicine
    Duke University (USA)

    Nassir F. Marrouche, MD
    Professor of Medicine
    Tulane University (USA)

    12:45 p.m. – 1:45 p.m.

    4005. Optimizing the Patient Care Pathway and LDL-C Management in Patients with Recent MI
    Industry-Expert Theater 1
    Sponsored by Amgen

    Please join us for a live presentation with Dr. Usman Baber and Dr. Benjamin Ansell about optimizing the patient care pathway and LDL-C management in patients with recent MI

    Usman Baber, MD, MS, FACC, FSCAI

    Benjamin Ansell, MD

    4013. Session Title To Be Announced
    Industry-Expert Theater 2
    Sponsored by Novartis Pharmaceuticals Corporation

    4021. Managing Today's Advanced Heart Failure Patient
    Industry-Expert Theater 3
    Sponsored by Cytokinetics

    This session will address the disease burden associated with advanced heart failure, review where care stands today, identify barriers to achieving guideline directed medical therapy (GDMT), and present management strategies for the advanced heart failure patient.

    Larry A. Allen, MD, MHS
    Professor of Medicine, Kenneth Poirier Endowed Chair
    Associate Head for Clinical Affairs, Cardiology
    Medical Director, Advanced Heart Failure
    University of Colorado, School of Medicine, Aurora, CO

    Gregg C. Fonarow, MD, FACC, FAHA, FHFSA
    Eliot Corday Professor of Cardiovascular Medicine and Science
    Interim Chief, UCLA Division of Cardiology
    Director, Ahmanson-UCLA Cardiomyopathy Center
    Co-Director, UCLA Preventative Cardiology Program
    David Geffen School of Medicine, UCLA

    Nasrien E. Ibrahim, MD
    Heart Failure & Transplant Cardiologist
    Director, Heart Failure Clinical Research
    Inova Heart & Vascular Institute, Falls Church, VA

    4037. An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C Description
    Industry Expert Theater 5
    Sponsored by Esperion Therapeutics

    The session will cover the following information:

    • Cardiovascular disease and its mortality and morbidity
    • Unique mechanism of action for two treatment options
    • Efficacy data for two treatment options
    • Safety data for two treatment options
    • Overview of the ongoing Outcomes trial

    Matthew Budoff, MD
    Professor of Medicine, UCLA
    Endowed Chair of Preventive Cardiology
    Lundquist Institute
    Torrance, CA

    3:45 p.m. – 4:45 p.m.

    4006. Help Your Recent MI Patients Achieve Lower LDL-C and Reduce the Risk of Another MI
    Industry-Expert Theater 1
    Sponsored by Amgen

    Join Dr. Richard Wright for an educational presentation on the treatment of very high-risk ASCVD patients described in the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. Hear about his experience and the treatment options available for appropriate patients.

    Richard F. Wright, MD, FACC

    4014. How Does Paradise Renal Denervation Fit Into Hypertension Treatment Management?
    Industry-Expert Theater 2
    Sponsored by ReCor Medical

    This session is to discuss the recent clinical developments with the ultrasound renal denervation procedure. The experts will review the consensus statements and guidelines for renal denervation and discuss the patient screening and preference.

    • Session objectives and introduction
    • Review of consensus statements and guidelines: what is needed next?
    • State of RDN today, the Paradise System and recent clinical developments
    • Who is the appropriate patient and how do we manage the referral pattern?
    • Q&A and key learnings

    Ajay J. Kirtane, MD, SM
    Associate Professor of Medicine at Columbia University Irving Medical Center (CUIMC) and Director of the Cardiac Catheterization Laboratories at New York-Presbyterian (NYP) Hospital /CUIMC

    Michael J. Bloch, MD, FACP, FASH, FNLA, FSVM
    Associate Professor, Department of Internal Medicine, University of Nevada School of Medicine, Medical Director, Vascular Care, Renown Heart and Vascular Institute, Reno, NV

    Michael A. Weber, MD, FACP, FACC, FAHA
    Professor of Medicine Division of Cardiovascular Medicine State University of New York, Downstate Medical Center
    Editor-in-Chief Emeritus, The Journal of Clinical Hypertension

    4022. A Practical Approach to Shared Decision Making When Treating Heart Valve Disease
    Industry-Expert Theater 3
    Sponsored by Medtronic

    Drs. Herrmann and Parwani along with Valve Program Coordinator, Kristin Pasquarello, and Patient Advocate, Adam Pick, will share their diverse perspectives and tangible examples on how heart teams can embed shared decision making into daily practice.

    Purvi Parwani, MBBS, MPH, FACC
    Director, Women's Cardiovascular Health Clinic, International Heart Institute Loma Linda University Medical Center

    Milind Desai, MD, MBA, FACC, FAHA, FESC
    Medical Director, Aortic Center Heart and Vascular Institute, Cleveland Clinic

    Howard Herrmann, MD
    Director, Cardiac Catheterization Laboratories and Health System Director for Interventional Cardiology at the Hospital of the University of Pennsylvania, Philadelphia

    Kristin Pasquarello, PA
    Administrative Director of the Heart Valve Center, St. Francis Hospital

    Adam Pick
    Patient Advocate, Author & Website Founder of

    4030. Stroke Prophylaxis: Treating the Untreated
    Industry-Expert Theater 4
    Sponsored by Boston Scientific

    Even with the recent advancements in pharmacologic and interventional treatments for prevention of stroke, there exists a large population of NVAF patients unprotected from stroke risk. This program will feature a multi-disciplinary panel of cardiologists, neurologists, and electrophysiologists sharing their experience in the management of their NVAF patients. The program will address gaps in AF-related stroke care, while providing an update on current clinical and real-world data supporting the evolution of stroke risk reduction strategies.

    • Gaps in AF-Related Stroke Risk
    • The Heart-Brain Team for Stroke Protection
    • Clinical Data and Real-World Evidence
    • Next Generation Stroke Reduction
    • Discussion

    C. Michael Gibson, MD, FACC (Moderator)
    Beth Israel Lahey Medical Center

    Kenneth Ellenbogen, MD
    Medical College of Virginia

    James Freeman, MD, MPH, MS
    Yale School of Medicine

    Christopher Granger, MD, FACC
    Duke Cardiology

    Mingming Ning, MD, MMSc
    Massachusetts General

    MONDAY, MAY 17

    9:45 a.m. – 10:45 a.m.

    4015. A Review of the RADIANCE-HTN Global Clinical Trial Program: A Focus on the TRIO Cohort
    Industry-Expert Theater 2
    Sponsored by ReCor Medical

    This session is to review the results and to hear expert discussion and takeaways from the RADIANCE-HTN TRIO cohort (blinded, sham-controlled, powered to demonstrate BP lowering effectiveness at 2 months).

    • Session objectives and introduction
    • Paradise Ultrasound Renal Denervation: the technologies, and potential benefits of ultrasound approach
    • RADIANCE-HTN Global Clinical Program: an overview, history of the field
    • RADIANCE-HTN TRIO: a review of study design and discussion of its primary analysis and outcomes
    • RADIANCE-HTN TRIO: what does this mean for the field? Who is the right patient for this therapy?
    • Q&A and key learnings

    Michel Azizi MD, PhD
    Professor of Vascular Medicine, Université Paris-Descartes, Paris, France & AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department
    Paris, France

    Naomi DL Fisher MD
    Director, Hypertension Specialty Clinic & Hypertension Innovation
    Division of Endocrinology, Diabetes and Hypertension
    Associate Professor of Medicine Harvard Medical School
    Boston, MA

    Chandan Devireddy, MD, FACC, FSCAI
    Associate Professor of Medicine
    Director, Cardiac Catheterization Laboratory-EUHM
    Associate Director, Interventional Cardiology Fellowship
    Emory University School of Medicine
    Emory University Hospital Midtown
    Atlanta, GA

    4023. Session Title To Be Announced
    Industry-Expert Theater 3
    Sponsored by GE Healthcare

    4031. Session Title To Be Announced
    Industry-Expert Theater 4
    Sponsored by ZOLL

    11:30 a.m. – 12:30 p.m.

    4008. Session Title To Be Announced
    Industry-Expert Theater 1
    Sponsored by Lilly

    4016. Advancing Patient Care Across the Heart Failure Continuum
    Industry-Expert Theater 2
    Sponsored by Abbott

    Heart failure is a complex, progressive disease with a 24% increase in mortality in recent years. It has become increasingly important to recognize when medications alone are not enough and referral to device interventions may be required. In this program, cardiology experts will discuss the latest device advancements, treatment guidelines and clinical data in the treatment and management of heart failure patients across the disease continuum. The latest updates on CardioMEMS™ HF System, MitraClip™ Therapy and HeartMate 3™ LVAD Therapy will be presented along with an expert panel discussion.

    JoAnn Lindenfeld, MD, FACC
    Director, Heart Failure & Transplantation Section
    Vanderbilt Heart & Vascular Institute

    Paul D. Mahoney, MD, FACC, FSCAI
    Director, Structural Heart Programs
    Sentara Heart Hospital

    Andrew J. Sauer, MD Medical Director, Center for Advance Heart Failure and Heart Transplantation,
    Associate Professor of Medicine – Cardiology
    University of Kansas Medical Center

    Jennifer A Cowger, MD, MS, FACC
    Medical Director, Mechanical Circulatory Support Program
    Henry Ford Hospital, Detroit, MI

    4024. Coronary IVL's Who, What, Where, When & Why: An Introductory Guide for Clinical Practice
    Industry-Expert Theater 3
    Sponsored by Shockwave Medical

    Presentations include:

    • Who: Interventionalists' Unmet Needs in Calcium Modification
    • What: Principles of Coronary IVL
    • Where: IVL's High Value Anatomical Locations
    • When: Insights from OCT Sub-Analysis of CAD III
    • Why: IVL Clinical Evidence – the Latest Insights from Disrupt CAD I,II, III,& IV Pooled Analysis
    • Discussion/Q&A

    Dean Kereiakes
    Bobby Yeh
    Ziad Ali
    Philippe Genereux
    Richard Shlofmitz
    Robert Riley

    Information current as of March 31, 2021.

    Industry-Expert Theater presentations are not part of ACC.21, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

    ACC Logo
    ACC.21 on Social Media:
    2021 American College of Cardiology Foundation. Visit
    Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us